Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	Stanford University National Institutes of Health (NIH)
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00186355

Purpose

To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Condition	Intervention
Lymphoma, Non-Hodgkin	Procedure: high dose chemo then auto hematopoietic cell transplant

MedlinePlus related topics: Lymphoma

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma

Further study details as provided by Stanford University:

Primary Outcome Measures:

PCR positivity in peripheral blood cell collections after cyclophosphamide

Secondary Outcome Measures:

Enrichment of hematopoietic stem cells
Engraftment

Estimated Enrollment:	80
Study Start Date:	October 2003

Detailed Description:

To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Eligibility

Ages Eligible for Study:	up to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:- relapsed NHL
 Exclusion Criteria:- liver dysfunction

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186355

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

National Institutes of Health (NIH)

Investigators

Principal Investigator:

Robert S Negrin

Stanford University

More Information

Study ID Numbers:	BMT4IJ, 77063, BMT41J, BMT4IJ, NCT00186355
Study First Received:	September 13, 2005
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00186355
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Lymphatic Diseases
Immunoproliferative Disorders
Lymphoma, small cleaved-cell, diffuse

Lymphoproliferative Disorders
Lymphoma, Non-Hodgkin
Lymphoma

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 15, 2009